What are the best treatments for Hajdu-Cheney Syndrome?

Hajdu-Cheney syndrome is an extremely rare genetic connective tissue disorder, and currently, there is no single curative treatment; instead, management focuses on multidisciplinary supportive care to address skeletal fragility and systemic complications. Treatment is highly personalized, often involving bisphosphonates to manage bone density and surgical interventions to address specific skeletal deformities or neurological symptoms.

What are the primary clinical treatments for Hajdu-Cheney syndrome?

Because Hajdu-Cheney syndrome is characterized by acro-osteolysis (the resorption of terminal phalanges) and severe osteoporosis, the primary pharmacological goal is to increase bone mineral density. Physicians frequently prescribe bisphosphonates, such as alendronate (Fosamax) or zoledronic acid (Reclast), to help stabilize bone turnover. While these medications are not curative, they are often used to mitigate the progressive bone loss seen in patients with Hajdu-Cheney syndrome.

What non-pharmacological interventions are used?

Management of Hajdu-Cheney syndrome requires a comprehensive approach to maintain functional independence and quality of life. Non-pharmacological interventions include:

• Physical Therapy: To improve mobility, maintain joint range of motion, and build supportive muscle strength.


• Occupational Therapy: To provide assistive devices that accommodate for hand/finger bone resorption.


• Orthopedic Surgery: Necessary for addressing severe spinal deformities, such as scoliosis or basilar invagination, which can cause neurological compression.


• Dental Care: Specialized monitoring is required due to the early-onset tooth loss associated with Hajdu-Cheney syndrome.

Which specialists should be on a care team?

A multidisciplinary team is essential for managing the systemic nature of Hajdu-Cheney syndrome. A typical team includes a clinical geneticist, a pediatric or adult endocrinologist (to manage bone health), an orthopedic surgeon, a physical therapist, and a dentist or orthodontist. At DiseaseMaps.org, our community of 5 individuals living with Hajdu-Cheney syndrome emphasizes the importance of coordinating care across these specialties to avoid fragmented treatment.

How does treatment effectiveness vary?

Treatment effectiveness varies significantly based on the age of diagnosis and the specific mutations in the NOTCH2 gene. Because Hajdu-Cheney syndrome is so rare, there are currently no large-scale clinical trials; most treatment protocols are derived from expert consensus and small case studies. Patients must work closely with their care team to monitor bone density scans and neurological function to adjust their management plan over time.

Next steps

• Consult with a geneticist to confirm the NOTCH2 mutation and establish a baseline for systemic monitoring.


• Connect with the 5 members of the DiseaseMaps community currently living with Hajdu-Cheney syndrome to share experiences and care strategies.


• Maintain regular dual-energy X-ray absorptiometry (DEXA) scans to track bone density changes.

Medical disclaimer: This information is for educational purposes only and does not constitute medical advice; please consult with your healthcare team to develop a treatment plan tailored to your specific clinical needs.

References

• NIH Genetic and Rare Diseases Information Center (GARD): Hajdu-Cheney Syndrome Overview.


• Orphanet: Rare Disease Database (ORPHA:393).


• OMIM (Online Mendelian Inheritance in Man): NOTCH2-related disorders (#102500).


• PubMed: Current literature on bisphosphonate therapy in rare acro-osteolysis syndromes.